(S) -Hydroxychloroquine

CAT: 0804-HY-B1370A-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B1370A-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
(S) -Hydroxychloroquine ((S) -HCQ) is the enantiomer of Hydroxychloroquine[1]. Hydroxychloroquine, a synthetic antimalarial agent, inhibits Toll-like receptor 7/9 (TLR7/9) signaling, and shows efficiently inhibits SARS-CoV-2 infection in vitro[2][3][4].
CAS Number
[137433-24-0]
Product Name Alternative
(S) -HCQ
UNSPSC
12352005
Hazard Statement
H315-H319-H320
Target
Autophagy; Parasite; SARS-CoV; Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Anti-infection; Autophagy; Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/s-hydroxychloroquine.html
Solubility
10 mM in DMSO
Smiles
CCN(CCO)CCC[C@@H](NC1=CC=NC2=CC(Cl)=CC=C12)C
Molecular Formula
C18H26ClN3O
Molecular Weight
335.87
Precautions
P264-P280-P302+P352-P305+P351+P338-P362
References & Citations
[1]Cardoso CD, et al. Enantioselective analysis of the metabolites of hydroxychloroquine and application to an in vitro metabolic study. J Pharm Biomed Anal. 2005 Apr 1;37 (4) :703-8.|[2]Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4 (1) :6.|[3]Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85 (3) :429-40.|[4]Yao X, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) . Clin Infect Dis. 2020 Mar 9. pii: ciaa237.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
Plasmodium; TLR7; TLR9

Popular Products